Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

An Integrative Approach to Probing Transient Protein Structures in Cell Extracts

To function correctly, cellular proteins depend not only on their complex tertiary and quaternary structures, but also on their proximity to and interactions with other molecules participating in the same metabolic or enzymatic pathway. Characterizing such top

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

To function correctly, cellular proteins depend not only on their complex tertiary and quaternary structures, but also on their proximity to and interactions with other molecules participating in the same metabolic or enzymatic pathway. Characterizing such topography and interactions is vital to a full understanding of cell function and dysfunction.

But visualizing and characterizing native protein-protein interactions remains a challenge, not least because of the complexity and size of protein structures within the cell. To date, most insights into protein function have come from analytical techniques that destroy higher order protein structure and disrupt the spatial arrangements that are vital for effective function.

Fortunately, a new era for cell and structural biology has dawned. Novel sample preparation techniques coupled with the advent of cryogenic electron microscopy (cryo-EM) and advances in complementary techniques, such as mass spectrometry (MS), mean it is now possible to visualize and interrogate large protein complexes in a near-native state. Already, technological and computational advances have produced an explosion of data on protein structure and function.

New integrative methods are enabling a holistic approach to structural biology. Consequently, transient scaffolds and subunits that used to be undetectable can now be revealed, improving our knowledge of the cell’s ultrastructure and offering new avenues for drug discovery.

A new perspective on protein architecture

Cell architecture and protein stoichiometry are vital for correct cell functioning, Yet the mechanical and chemical methods commonly used to isolate cellular proteins disrupt a myriad of finely controlled interactions between protein subunits and complexes. Research to explore catalytic pathways is often reductionist—identifying individual constituents before adding purified components together, mostly after heterologous expression, to test and monitor interactions.

A novel, more holistic approach provides a new perspective. It uses cell extracts to keep protein complexes intact and in natural proximity to other proteins, allowing scientists to study higher order protein architecture and organization. The extracts can be investigated using a range of cutting-edge visualization, analytical, and functional assays, many of which allow proteins to be studied in a native state.

Data generated using innovative techniques, such as cryo-EM to visualize proteins and crosslinking MS (XL-MS) to identify and characterize them, is complemented by information from functional assays and advanced computational biology to reveal previously unseen details of intricate protein-protein interactions within the cell. This integrated approach, further fueled by technological and digital automation, is pushing forward the frontiers of cell biology and classical structural biology.

Novel structural and nonstructural elements revealed

The benefits of this integrative structural biology approach can be illustrated by the pyruvate dehydrogenase complex (PDHc), which is a giant, 10-megadalton enzymatic assembly, ubiquitous in eukaryotic cells, that converts pyruvate to acetyl coenzyme A. Multiple PDHc components have been characterized in isolation and localized to the mitochondrial inner membrane–matrix interface, but the complex’s quaternary structure has remained elusive due to its sheer size, heterogeneity, and plasticity.

Paradoxically, previous studies have identified structural components overlaying the pyruvate binding site, raising the question of how the substrate enters and effectively binds at the site.

Recently, investigators have taken a more holistic approach to better understand the structural organization of PDHc (Figure 1). They enriched cell extracts from a thermophilic fungus and employed a range of analytical assays, including MS and cryo-EM, to reveal, for the first time, the active structure of the ubiquitous PDHc.1

Large protein complexes, isolated from cell lysates using size-exclusion chromatography (SEC), were visualized at the atomic level using cryo-EM and their composition determined using MS techniques. Chemical XL-MS, which uses chemicals to stabilize protein-protein interactions ahead of MS analysis, helped pinpoint interactions in the protein assemblies.

Linking the resulting MS data to molecular signatures identified in cryo-EM micrographs has revealed a multitude of structures, including the fatty acid synthase metabolon, double- and single-membrane structures, liposomes with encapsulated biomolecules, and other higher order complexes.2

This integrated approach has provided new insights into the three-dimensional structure of the PDHc binding site and proved for the first time that it is accessible to the pyruvate substrate. This approach also unveiled an asymmetric protein configuration directly involved in pyruvate oxidation.1

The big reveal came when a giant nanocompartment was visualized for the first time—a transient catalytic chamber called the “pyruvate dehydrogenase factory.” It is likely to be the first of many similar structures identified using these methods (Figure 2).

Changing the interface for cell and structural biology

Technologies, such as MS and cryo-EM, continue to advance at pace, together with functional and biophysical assays. Added to that, automation and machine learning tools have increased throughput and efficiency and have led to an explosion in datasets that allow investigators to take a much broader view of intricate protein interactions. Generating large datasets makes it possible to mine data distributions rather than single data points. Moreover, large datasets provide investigators with new opportunities to interrogate cellular processes and identify points for intervention.

Additionally, machine learning–inspired algorithms are enhancing image processing workflows to accelerate analyses of thousands of protein interactions.3 This high-resolution, high-throughput approach is revealing distinct structural signatures. These signatures can be correlated with proteomic data and cryo-EM maps to characterize previously unidentified protein communities at high resolution.

It is this integrated approach that is providing new insights into molecular organization at near atomic scale and revealing novel protein-protein interactions that are vital for correct cell function.4 Undoubtedly, these insights will take drug discovery beyond an enzyme’s active site to other specific points of protein interaction.

New horizons for drug discovery

There is still a great deal to learn about the cell’s proteome and its exact architecture. Bringing together a combination of biological and biophysical assays into an integrative model, using cell extracts and purified molecules, provides enormous potential for solving the most challenging questions of cell structure and function.

The integrative approach offers a bridge to combine data on purified proteins and subunits with visual and analytical data on larger complexes in their native state, at an unprecedented resolution.

For the first time, transient protein structures that are vital for enzyme activity can be visualized and investigated. And automation and machine learning are transforming the scale and rate at which new insights can be acquired, as witnessed recently with the AlphaFold and RoseTTAFold projects for the prediction of three-dimensional structures of proteins and their interactions.

All this is providing inspiration for new avenues of enquiry. But to push the technologies to the limits, investigators must work together and develop a coherent model that can be applied across laboratories and used by investigators in different disciplines.

Within a decade, the pieces of the cellular puzzle should be in place. A full inventory of cellular protein structures is in sight, and integrated data on how the cell functions and is organized is on the horizon. Critically, the wide implementation of an integrated analytical approach, using state-of-the-art and emerging technologies, is necessary to underpin this explosion in knowledge and accelerate and expand the scope of drug discovery in years to come.

References

1. Kyrilis FL, Semchonok DA, Skalidis I, et al. Integrative structure of a 10-megadalton eukaryotic pyruvate dehydrogenase complex from native cell extracts. Cell Rep. 2021; 34: 108727. DOI: 10.1016/j.celrep.2021.108727.

2. Skalidis I, Tüting C, Kastritis PL. Unstructured regions of large enzymatic complexes control the availability of metabolites with signaling functions. Cell Commun. Signal. 2020; 18(1): 136. DOI: 10.1186/s12964-020-00631-9

3. Kyrilis FL, Belapure J, Kastritis PL. Detecting Protein Communities in Native Cell Extracts by Machine Learning: A Structural Biologist’s Perspective. Front. Mol. Biosci. 2021; 8: 660542. DOI: 10.3389/fmolb.2021.660542.

4. Tüting C, Kyrilis FL, Müller J, et al. Cryo-EM snapshots of a native lysate provide structural insights into a metabolon-embedded transacetylase reaction. Nat. Commun. 2021; 12: 6933. DOI: 10.1038/s41467-021-27287-4.

Panagiotis L. Kastritis, PhD ([email protected]), is junior professor of cryo-electron microscopy and computational structural biology at the Interdisciplinary Research Center HALOmem, Charles Tanford Protein Center Institute of Biochemistry and Biotechnology, Martin Luther University Halle-Wittenberg, Germany.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →